Anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in TAA induced mouse model of liver injury and fibrosis

被引：0
|
作者：
Kim, J. [1 ]
Lee, J. [1 ]
Kim, Y. [1 ]
Lee, S. [1 ]
Kwon, H. [1 ]
Park, E. [1 ]
Choi, J. [1 ]
Bae, S. [1 ]
Kim, D. [1 ]
Lee, S. [1 ]
Choi, I. [1 ]
机构：
[1] Hanmi Phaarm Co Ltd, Seoul, South Korea
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
778
引用
收藏
页码：S400 / S401
页数：2
相关论文
共 50 条
  • [21] Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice
    Kim, Jung Kuk
    Lee, Jong Suk
    Kwon, Hyunjoo
    Lee, Jongsoo
    Kim, Daejin
    Bae, Sungmin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2020, 69
  • [22] Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis
    Lee, Jong Suk
    Kim, Yohan
    Kim, Jung Kuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Kim, Jeong A.
    Park, Sang Hyun
    Bae, Sung Min
    Lee, Sang Hyun
    Choi, In Young
    JOURNAL OF HEPATOLOGY, 2023, 78 : S779 - S780
  • [23] Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
    Kim, W.
    Kim, J.
    Lee, S. -H.
    Bae, S.
    Choi, I.
    Kim, Y.
    DIABETOLOGIA, 2019, 62 : S292 - S292
  • [24] Bone Protective Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in an Animal Model
    Lee, Sangdon
    Kim, Yu-Yon
    Lee, Jong Suk
    Lee, Sang Hyun
    Kim, Young Hoon
    Choi, In Young
    Kim, Sun Jin
    DIABETES, 2018, 67
  • [25] Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a Dyslipidemia Animal Model
    Choi, Jaehyuk
    Jo, Hyosang
    Kim, Jung Kuk
    Lee, Sang Don
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2019, 68
  • [26] Bone protective effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in an animal model
    Lee, S.
    Kim, Y. -Y.
    Lee, J.
    Lee, S. -H.
    Kim, Y.
    Choi, I.
    Kim, S.
    DIABETOLOGIA, 2018, 61 : S244 - S245
  • [27] Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models
    Kim, Jeong A.
    Lee, Sangdon
    Lee, Sang Hyun
    Jung, Sung Youb
    Kim, Young Hoon
    Choi, In Young
    Kim, Sun Jin
    DIABETES, 2018, 67
  • [28] THERAPEUTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN CDHFD-INDUCED MOUSE MODEL OF NASH AND FIBROSIS MICE
    Choi, Jaehyuk
    Lee, Seon Myeong
    Kim, Jung Kuk
    Jo, Hyo Sang
    Lee, Jong Suk
    Kwon, Hyunjoo
    Bae, Sung Min
    Kim, Dae Jin
    Lee, Sang Hyun
    Choi, In Young
    HEPATOLOGY, 2020, 72 : 1039 - 1039
  • [29] Effect of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in a dyslipidaemia animal models
    Jo, H.
    Kim, J.
    Choi, J.
    Lee, S.
    Lee, S. -H.
    Choi, I.
    DIABETOLOGIA, 2019, 62 : S510 - S511
  • [30] Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in NASH and fibrosis animal models
    Kim, J.
    Choi, I.
    Lee, J.
    Park, E.
    Kim, Y.
    Jung, S.
    Kim, S.
    DIABETOLOGIA, 2018, 61 : S61 - S62
12345